Emcure to take full control of Gennova Biopharma with ₹232 crore stake acquisition
Emcure Pharmaceuticals is acquiring the remaining 12.05% stake in Gennova Biopharmaceuticals for ₹232 crore to gain full control. The move includes a leadership transition to focus on biologics and biosimilars.
Why it matters
Consolidating ownership in biotech subsidiaries is a strategic move for pharmaceutical companies to streamline R&D and focus on high-growth therapeutic areas.
Emcure Pharmaceuticals on Monday (July 13, 2026) said it is acquiring remaining 12.05% stake in subsidiary Gennova Biopharmaceuticals in a ₹232 crore deal.
The article is a standard corporate announcement regarding an acquisition and leadership change.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in